Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Show more

Location: Tuborg Boulevard 12, Hellerup, 2900, Denmark | Website: https://ascendispharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

10.41B

52 Wk Range

$111.09 - $183.00

Previous Close

$172.00

Open

$170.19

Volume

270,610

Day Range

$170.19 - $174.34

Enterprise Value

10.75B

Cash

517.9M

Avg Qtr Burn

-54.73M

Insider Ownership

0.78%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

SKYTROFA (TransCon hGH) (lonapegsomatropin) Details
Pediatric growth hormone deficiency

Approved

Quarterly sales

TransCon CNP Details
Achondroplasia

PDUFA

Approval decision

TransCon hGH Details
Adult growth hormone deficiency

PDUFA

Approval decision

Phase 2

Data readout

Phase 2

Data readout

TransCon hGH Details
Turner syndrome

Phase 2

Data readout

Phase 2

Data readout

TransCon IL-2 B/y Details
Cancer, Solid tumor/s

Phase 2

Data readout

TransCon CNP Details
Achondroplasia

Phase 2

Update